Table 2.
Permeability (P e 10−6 cm ⋅ s−1) in the PAMPA‐BBB assay of 14 commercial drugs and tested compounds and predictive penetration in the CNS.
|
Compound |
Bibliography value [33] |
Compound |
Bibliography value [33] |
|---|---|---|---|
|
Verapamil |
16.0 |
25.9 ±0.8 |
|
|
Testosterone |
17.0 |
26.6±0.9 |
|
|
Corticosterone |
5.1 |
6.7±0.1 |
|
|
Clonidine |
5.3 |
6.5±0.06 |
|
|
Ofloxacin |
0.8 |
0.1±0.09 |
|
|
Lomefloxacin |
0.0 |
0.8±0.05 |
|
|
Progesterone |
9.3 |
14.7±0.3 |
|
|
Promazine |
8.8 |
13.8±0.4 |
|
|
Imipramine |
13.0 |
16.8±0.3 |
|
|
Hydrocortisone |
1.9 |
1.4±0.06 |
|
|
Piroxicam |
2.5 |
2.0±0.08 |
|
|
Desipramine |
12.0 |
17.8±0.2 |
|
|
Cimetidine |
0.0 |
0.7±0.02 |
|
|
Norfloxacin |
0.1 |
8.8±0.4 |
|
|
E |
|
2.2±0.1 |
CNS+/‐ |
|
F |
|
10.9±0.4 |
CNS+ |
|
H |
|
17.4±2.4 |
CNS+ |